

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Abbisko Cayman Limited**  
**和譽開曼有限責任公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2256)**

**POSITIVE PROFIT ALERT**

This announcement is made by Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the Group’s unaudited management accounts for the six months ended June 30, 2024, (i) the total revenue of the Group for the six months ended June 30, 2024 is expected to be approximately RMB497 million, representing an increase of RMB478 million from approximately RMB19 million for the six months ended June 30, 2023; and (ii) the Group is expected to record a profit for the period within the range of RMB200 million to RMB220 million for the six months ended June 30, 2024, compared to a loss for the period of approximately RMB209 million for the six months ended June 30, 2023. Apart from the improved cost control through enhanced business operation efficiency, the anticipated increase in total revenue and turnaround from loss to profit were also mainly attributable to the out-licensing agreement for pimicotinib (ABSK021) and the upfront payment of US\$70 million (RMB497 million) with MERCK HEALTHCARE KGAA, which contributed significantly to the revenue for the six months ended June 30, 2024.

As at the date of this announcement, the Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2024. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the six months ended June 30, 2024 currently available to the Company, and is not based on any figures or information which have been reviewed or confirmed by the audit committee of the Board, or reviewed or audited by the auditors of the Company. The actual results of the Group for the six months ended June 30, 2024 may differ from those disclosed in this announcement. They shall not be taken as a measure or indication of the Group's current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Company's interim results announcement for the six months ended June 30, 2024, which is expected to be published by the end of August 2024 in accordance with the requirements of the Listing Rules. As such, the above figures are provided for Shareholders' and potential investors' reference only. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended June 30, 2024.

By order of the Board  
**Abbisko Cayman Limited**  
**Dr. Xu Yao-Chang**  
*Chairman*

Shanghai, July 10, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.*